rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
B-raf V600E protein analysis revealed a subjacent layer of heterogeneity for mutation-positive metastatic melanomas.
|
31835364 |
2019 |
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Here we discuss the role of ERK signaling in cell fate, in driving melanoma, and in resistance mechanisms to current BRAF-V600E melanoma treatments.
|
31190430 |
2019 |
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Notorious oncogenic BRAF V600E plays a significant role in the signal transduction of the MAPK pathway, which is involved in tumor growth, especially in melanoma.
|
30630714 |
2019 |
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
BRAF inhibitors (BRAFi) have been applied to treat melanoma harboring V600E mutations.
|
30829029 |
2019 |
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
To anticipate possible resistance to ERK inhibitors (ERKi), we used SCH772984 (SCH) as a model ERKi to characterize resistance mechanisms in two BRAF V600E melanoma cell lines.
|
30833419 |
2019 |
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Our results demonstrated that the BRAF V600E mutation is a frequent event in Indian melanomas, and represents an important molecular target for novel therapeutic approaches.
|
30803557 |
2019 |
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The identification of the V600E activating mutation in the protein kinase BRAF in around 50% of melanoma patients has driven the development of highly potent small inhibitors (BRAFi) of the mutated protein.
|
31401373 |
2019 |
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The present study aims to assess the prevalence and prognostic significance of BRAF V600E mutation and apprehend its association with clinicopathologic features in stage I to III Turkish melanoma patients.
|
31058533 |
2019 |
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
We established vemurafenib-resistant (VR) cells from three BRAF (V600E)-mutated melanoma lines (C32, HMY-1, and SK-MEL-28) and evaluated the mechanism of acquired resistance of VR cells by water-soluble tetrazolium salts assay, western blot, real-time quantitative PCR, and immunofluorescent microscopy.
|
30920401 |
2019 |
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
AHR activation induces the expression of resistance genes against the inhibitors of V600E mutated B-Raf proto-oncogene, serine/threonine kinase (BRAF) in melanoma and upregulation of programmed cell death protein 1 (PD-1) in tumor-infiltrating T cells surrounding melanoma.
|
31552251 |
2019 |
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Vemurafenib is a B-Raf V600E inhibitor that exerts significant inhibitory effects in melanoma but not in colon cancer, and the mechanism of vemurafenib resistance remains unclear.
|
30872078 |
2019 |
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Patients with rare <i>BRAF</i> mutations can respond to targeted therapy, however, efficacy seems to be lower compared with V600E mutated melanoma.
|
31580757 |
2019 |
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The combination of a BRAF inhibitor dabrafenib and a MEK inhibitor trametinib (CombiDT) has improved outcomes compared with chemotherapy or BRAF inhibitor monotherapy in advanced BRAF V600E/K melanoma.
|
30661097 |
2019 |
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Here, we tested the BETi, PLX51107, for immune-based effects on tumor growth in BRAF V600E melanoma syngeneic models.
|
31063649 |
2019 |
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Specific mutations of RAF kinases, such as the prevalent BRAF(V600E) mutation in melanoma, or defects in upstream signaling or feedback loops cause decoupled kinase activities which lead to tumorigenesis.
|
28466200 |
2019 |
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Sixty five consecutive formalin-fixed paraffin-embedded (FFPE) melanoma samples were prospectively tested for BRAF mutations with the VE1 (anti-BRAF V600E) antibody and for both BRAF and NRAS mutations with the Idylla NRAS-BRAF-EGFR S492R Mutation Assay cartridges.
|
31415669 |
2019 |
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
This study thus defined SPRY4 as a potential mediator of synthetic suppression, which is likely to contribute to the observed exclusivity between BRAF(V600E) and NRAS(Q61R) mutations in melanoma.
|
30651601 |
2019 |
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Patients with BRAF V600E-mutated melanoma respond to FDA-approved BRAF inhibitors.
|
29271794 |
2019 |
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Our data suggest indoor tanning may promote melanomas that arise in skin with low-chronic sun-induced damage through BRAF V600E-mediated melanomagenesis.
|
30923800 |
2019 |
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The presence of a BRAF V600E mutation and activation of ERK, MEK, S6, and AKT were assessed with immunohistochemistry in 35 conjunctival nevi and 31 melanomas.
|
31247083 |
2019 |
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Vemurafenib and dabrafenib are B-Raf<sup>V600E</sup> inhibitors that were approved for the treatment of melanomas bearing the V600E mutation.
|
30118796 |
2018 |
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
We suggest that using primary melanoma tissues is just as safe as using metastatic tissue for detection of BRAF V600E, as BRAF intertumour heterogeneity is extremely rare.
|
29119584 |
2018 |
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
This study evaluated the safety and tolerability, pharmacokinetics (PK) and preliminary efficacy of dabrafenib 150 mg b.i.d. plus trametinib 2 mg q.d. in Japanese patients with BRAF V600E/K mutant solid tumors (phase 1) and melanoma (phase 2).
|
29399853 |
2018 |
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
To test whether the BRAF inhibitors dabrafenib and vemurafenib together with ionizing radiation more effectively inhibit melanoma cells, primary human melanoma tumor cell lines expressing wild-type (WT) or mutant V600E BRAF were analyzed by cell survival, cell death, and cell-cycle testing.
|
29491057 |
2018 |
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Melanoma cell line A375 with BRAF V600E point mutation exhibits higher FRET efficiency than liver cancer cell line HegG2 that was not reported having the mutation at this point.
|
29766713 |
2018 |